Bioxodes obtient la désignation de médicament orphelin pour son candidat-médicament dans le traitement de l’AVC hémorragique aux États-Unis et en Europe
05. März 2025 02:30 ET
|
Bioxodes
La FDA et l’EMA accordent à BIOX-101 le statut de médicament orphelin pour traiter l’AVC hémorragiqueLe statut de médicament orphelin est susceptible d‘accélérer le développement et l’approbation du...
Bioxodes obtains Orphan Drug Designation for hemorrhagic stroke therapeutic candidate in US and Europe
05. März 2025 02:30 ET
|
Bioxodes
FDA, EMA grant BIOX-101 ODD status to treat intracerebral hemorrhagic stroke (ICH)ODD status may expedite drug candidate development and approvals BIOX-101 interim Phase 2a data in ICH imminent ...
Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering
27. Februar 2025 09:00 ET
|
Amarin Corporation plc
-- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events by 34% Among Patients with...
National Board of Echocardiography and Inteleos Form Cardiovascular Imaging Coalition to Launch Innovative Multimodality Certification Program
20. Februar 2025 15:01 ET
|
Inteleos, Inc.
The National Board of Echocardiography (NBE) and Inteleos have established the Cardiovascular Imaging Coalition (CVIC) to streamline MOC.
Nitinol-Based Medical Device Market to Reach $9.8 billion, Globally, by 2035 at 7.1% CAGR: Allied Market Research
19. Februar 2025 06:26 ET
|
Allied Market Research INC
Wilmington, Delaware, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Nitinol-Based Medical Device Market by Product Type (Stents, Guidewires, Retrieval device,...
[Latest] Global Empty Capsules Market Size/Share Worth USD 4.61 Billion by 2034 at a 5.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
19. Februar 2025 03:30 ET
|
Custom Market Insights
Austin, TX, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Empty Capsules Market Size, Trends and Insights By Type (Gelatin Capsules,...
Bioxodes obtient de nouveaux financements qui permettront de franchir les jalons début 2025 et de poursuivre son financement de Série B
12. Februar 2025 02:30 ET
|
Bioxodes
Bioxodes lève 2,7 millions d'euros auprès de ses investisseurs historiques dans le cadre d'une extension de la Série ADes données intermédiaires issues de l'étude de phase 2a sur l'hémorragie...
Bioxodes secures new funds to reach early 2025 milestones and pursue Series B financing
12. Februar 2025 02:30 ET
|
Bioxodes
Bioxodes raises €2.7 million from existing investors in Series A extensionInterim data from BIRCH intracerebral hemorrhage (ICH) Phase 2a trial in Q1 2025Recruitment of up to 16 additional patients...
Bioxodes atteint un premier objectif de recrutement pour l'essai de phase 2a sur l'hémorragie intracérébrale
19. Dezember 2024 02:30 ET
|
Bioxodes
Bioxodes a recruté les 16 premiers patients pour l'essai de BIOX-101Une analyse intermédiaire sera réalisée à la fin du traitement de la première cohorte de patientsBIOX-101 est un candidat...
Bioxodes meets enrollment milestone in Phase 2a intracerebral hemorrhagic stroke trial
19. Dezember 2024 02:30 ET
|
Bioxodes
Bioxodes has enrolled first 16 patients in trial with BIOX-101Completing treatment of first cohort of patients will trigger interim analysisBIOX-101 is a first-in-class drug candidate, a peptide...